Skip to content

MedDrive's Responsiveness to Alcohol

MedDrive's Responsiveness to Different Blood Alcohol Concentrations and Concurrent Validity Against Performances on a Driving Simulator; a Phase I, Randomised, Double Blind, Placebo, Dose Response Validation Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01781273
Acronym
OH-MedDrive
Enrollment
21
Registered
2013-01-31
Start date
2013-02-28
Completion date
2013-04-30
Last updated
2013-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired Driving

Keywords

impaired driving

Brief summary

This four-way, dose-response, crossover, double blind, placebo-controlled, randomised validation study investigates the responsiveness of MedDrive, a computed battery of neuropsychological tasks, to different doses of alcohol. The following hypothesis are tested: 1. Measures from MedDrive are influenced by alcohol in a dose dependent way. 2. Effects of alcohol on driving performances are correlated to measures from MedDrive in a dose dependent way. 3. Within a group of healthy young drivers, MedDrive shows consistent results over repeated measures (ICC≥0.7). 4. MedDrive models effects of alcohol on driving performances better than does the UFOV or the trial making task.

Detailed description

Background: There is an increasing need for physicians to advice patients on their fitness to drive. Current guidelines underline the limitations of existing instruments and the poor adaptability of batteries of neuropsychological tests assessing fitness to drive in both experimental and primary care settings. The investigators therefore developed MedDrive, a free, reliable, computer based measuring instrument capable of detecting effects of age and drugs on cognitive functions considered as essential for driving. Objectives: This study aims to test MedDrive responsiveness to different blood alcohol concentrations (BAC) and validate these measures against performances on a driving simulator. It also aims to measure MedDrive's reliability following repeated measures during the training phase, to compare MedDrive's performances in measuring effects of different BAC against the UFOV, and to model MedDrives measures to predict behaviour on the simulator. Finally, this study also includes a nested experimental study measuring effects of alcohol on attention. Methods: Using Widmark's formula, 16 healthy young drivers are given cranberry juice with different doses of ethanol to bring their BAC to 0 g/L, 0.5 g/L, 0.65 g/L, and 0.8 g/L. They are blinded to the presence of ethanol by inhaling vapors of ethanol just before drinking. BAC is maintained during the entire experiment by using a breathalyser and administrating drinks throughout the experiment. Three scenarios are planned on a driving simulator (StSoftware PvW-2010), a road tracking task, a car following task, and a car following task including dual tasking using peripheral vision.

Interventions

OTHEREthanol

During a 45 min period, investigators will ask participants to drink 500ml of cranberry juice, 100 ml at a time each 5 minutes. Depending of the allocation, these drinks will contain more or less alcohol. Pure ethanol will be used mixed with the beverage. The amount of alcohol to dilute in the drink will be calculated using Widmarks formula. Participants will move to the simulator room 20 minutes after having finished drinking the first 500 ml. To maintain the BAC level, investigators will use a breathalyser and provide 100 ml cranberry juice every 20 minutes with the amount of necessary alcohol. The person administrating drinks will hand over the drinks and make sure the participants breaths in before taking a sip, thereby inhaling alcohol vapour from the lid and keeping them blinded to the content.

100 mL cranberry juice is provided in a 250 ml container.

Sponsors

University of Lausanne Hospitals
CollaboratorOTHER
University Hospital, Geneva
CollaboratorOTHER
University of Lausanne
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged 20 to 40 years * Obtained drivers license at least 24 months before * Fit to drive * Consumed at least once six units of a beverage with alcohol at a single occasion during the previous six months

Exclusion criteria

* Under the influence of a medicinal drug affecting their driving performance * Suffer from a psychiatric condition affecting driving performances * Suffer from simulator sickness * Presenting criteria (ICD-10) of alcohol dependence. * Pregnant or breastfeeding * Intolerant to alcohol defined by having either headaches or digestive disorders for quantities of alcohol that do not seem to bother other people.

Design outcomes

Primary

MeasureTime frameDescription
spatial resolution decay1 hour post-interventionCorresponds to the loss in precision for each extra cue shown during the Memory Decay of Spatial Resolution Task (Task 4) in MedDrive (ln(mm)/cue).
orientation gain1 hour post-interventionCorresponds to the average gain in response time (ms) over the neutral condition after participants are shown where the peripheral stimuli is to show up during the Central Cue Attention Task (Task 2) in MedDrive.
attention shift response time1 hour post-interventionCorresponds to the average response time in ms to detect the orientation of a given moving target during the Movement Detection Task (Task 3) in MedDrive.
distance to first cue1 hour post-interventionCorresponds to the geometrical mean of distances in mm between the true location of the first cue and its indicated location during the Memory Decay of Spatial Resolution Task (Task 4) in MedDrive.
distance to last cue1 hour post-interventionCorresponds to the geometrical mean of distances in mm between the true location of the last cue and its indicated location during the Memory Decay of Spatial Resolution Task (Task 4) in MedDrive.
central visual processing time1 hour post-interventionCorresponds to the duration of exposure in ms for a 37.5% threshold for correct guesses adjusted for chance for central vision in the Visual Recognition Task (Task 1) in MedDrive.
peripheral visual processing time1 hour post-interventionCorresponds to the duration of exposure in ms for a 43.8% threshold for correct guesses adjusted for chance for peripheral vision in the Visual Recognition Task (Task 1) in MedDrive.
dual task processing time1 hour post-interventionCorresponds to the duration of exposure in ms for a 48.7% threshold for correct guesses adjusted for chance for simultaneous central and peripheral vision (dual tasking) in the Visual Recognition Task (Task 1) in MedDrive.
neutral response time1 hour post-interventionCorresponds to the average response time in ms adjusted for learning effect for participants to respond to a peripheral stimuli during the Central Cue Attention Task (Task 2) in MedDrive.
conditioned alerting gain1 hour post-interventionCorresponds to the average gain in response time (ms) over the neutral condition after participants are warned of the imminent exposure to a peripheral stimuli during the Central Cue Attention Task (Task 2) in MedDrive.

Secondary

MeasureTime frameDescription
Useful Field of View1 hour post-interventionThe UFOV is a neuropsychological task which provides four outputs: visual processing, divided attention, selective attention, and overall risk
Trial Making Task1 hour post-interventionThe duration of tasks TMT-A and TMT-B are provided in seconds
StSoftware driving simulator1 hour post-interventionStandard lateral deviation from the center of the road during the road tracking task, and gain and delay during the car following tasks

Other

MeasureTime frameDescription
Adverse events1 week after interventionNew symptoms, accidents, hospitalisation are recorded one week after each visit.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026